HOME >> BIOLOGY >> NEWS
JCI table of contents, 2 August, 2004

cell cycle might be involved in this mechanism as they are important for stimulating or inhibiting the growth of a variety of cell types, and likely affect the growth and repair of tissue damage. To test their hypothesis, they used mice that are defective in the production of a cell cycle molecule called p27kip1 and show that these mice, after experiencing mechanical damage to an artery, had increased lesion formation with increased infiltration by immune and inflammatory cells. When the researchers transplanted bone-marrow cells from p27kip1 defective mice into normal mice, these transplant mice had higher a higher prevalence of arterial blockage. To assess the importance of immune cells in the repair of vascular tissues, the authors looked at the vascular repair in mice that were transplanted with bone marrow from mice that are unable to make immune cells, these are called RAG deficient mice. Mice transplanted with normal bone marrow cells showed greatly exacerbated the vascular injury compared to mice transplanted with bone marrow cells from RAG deficient mice. The data here show a direct link vascular inflammation and proliferation, and indicate that treatment for cardiovascular disease should target factors involved in immunity and inflammation.

TITLE: Bone marrow-derived immune cells regulate vascular disease through a p27Kip1-dependent mechanism

AUTHOR CONTACT:
Elizabeth G. Nabel National Heart, Lung, and Blood Institute, NIH, 50 Center Dr, Bethesda, MD 20892, USA
Phone: 301-496-1518; Fax: 301-402-7560; E-mail: nabele@nhlbi.nih.gov

View the PDF of this article at: https://www.the-jci.org/press/20176.pdf

**************************************************************************************

Interferon Interference Obstructs Ducts

Biliary atresia is a disease in which bile flow is increasingly
'"/>

Contact: Laurie Goodman
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
2-Aug-2004


Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. JCI table of contents September 15, 2004
4. JCI table of contents: 1 September, 2004
5. Anti-cancer compound in vegetables found to block late-stage breast-cancer cell growth
6. JCI table of contents, 16 August, 2004
7. When male fish hum, females swim in, thanks to hormones, adaptable hearing
8. JCI table of contents, 1 July 2004
9. Search and destroy protein turns tables on HIV
10. JCI table of contents, 15 June 2004
11. JCI table of contents, 1 June 2004

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents August

(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: